NEW YORK (GenomeWeb News) – Molecular Diagnostics firm GenomeDx said today it has entered into agreements to provide laboratory testing as a participating provider with three preferred provider networks.

The PPOs are Stratose, Three Rivers Provider network, and Fortified Provider Network. The deals expand the number of covered lives with access to GenomeDx's Decipher prostate cancer classifier test by 62.6 million, the San Diego-based firm said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.